NA
FOLD

NewEdge Advisors’s Amicus Therapeutics FOLD Stock Holding History

NewEdge Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-585
Closed -$5.8K – 3857
2024
Q2 		$5.8K Sell
585
-564
-49% -$5.79K ﹤0.01% 3046
2024
Q1 		$13.5K Sell
1,149
-772
-40% -$9.87K ﹤0.01% 2768
2023
Q4 		$27.3K Buy
1,921
+1,336
+228% +$15.2K ﹤0.01% 2458
2023
Q3 		$7.11K Hold
585
– – ﹤0.01% 2694
2023
Q2 		$7.35K Hold
585
– – ﹤0.01% 2698
2023
Q1 		$6.49K Sell
585
-116
-17% -$1.43K ﹤0.01% 2696
2022
Q4 		$1.42K Buy
+701
New +$7.89K ﹤0.01% 2932

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NewEdge Advisors's FOLD Position: Q3 2024 in Review

NewEdge Advisors sold out of Amicus Therapeutics (FOLD) in Q3 2024, closing a stake of 585 shares — an estimated $5.8K sold.

NewEdge Advisors first reported a position in FOLD in Q4 2022 and held it in 7 quarters. The position peaked at $27.3K in Q4 2023. 293 funds tracked by Wall St. Rank hold FOLD as of Q3 2024.

  • NewEdge Advisors reported no remaining Amicus Therapeutics position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 585 Amicus Therapeutics shares in Q3 2024, an estimated $5.8K.
  • NewEdge Advisors first reported a position in Amicus Therapeutics in Q4 2022 and held it in 7 quarters.
  • NewEdge Advisors's Amicus Therapeutics position peaked at $27.3K in Q4 2023.
  • 293 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.